{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:54:56Z","timestamp":1790834096897,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.blre.2023.101042","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T12:21:38Z","timestamp":1674217298000},"page":"101042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"59","author":[{"given":"David","family":"Kegyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Jitaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0005","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0010","first-page":"47","article-title":"Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia","volume":"8","author":"Hefazi","year":"2018","journal-title":"Blood Lymphat Cancer [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2023.101042_bb0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2008.83","article-title":"CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL","volume":"22","author":"Kong","year":"2008","journal-title":"Leukemia [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/1074-7613(95)90157-4","article-title":"Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule","volume":"3","author":"Engel","year":"1995","journal-title":"Immunity [Internet]"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/10409238.2016.1215288","article-title":"The PI3K pathway in B cell metabolism","volume":"51","author":"Jellusova","year":"2016","journal-title":"Crit Rev Biochem Mol Biol [Internet]"},{"issue":"10","key":"10.1016\/j.blre.2023.101042_bb0040","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies","volume":"12","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101042_bb0045","series-title":"The regulation and function of CD20: An \u201cenigma\u201d of B-cell biology and targeted therapy","first-page":"1494","volume":"105","author":"Pavlasova","year":"2020"},{"issue":"25","key":"10.1016\/j.blre.2023.101042_bb0050","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0060","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"26","key":"10.1016\/j.blre.2023.101042_bb0070","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood [Internet]"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0075","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/bloodadvances.2021004284","article-title":"Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency","volume":"5","author":"Ramdeny","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ccr3.604","article-title":"Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant","volume":"4","author":"Khan","year":"2016","journal-title":"Clin Case Rep"},{"issue":"18","key":"10.1016\/j.blre.2023.101042_bb0085","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0090","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2147\/TCRM.S84261","article-title":"Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults","volume":"12","author":"Lee","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101042_bb0095","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2021-150018","article-title":"Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R\/R B-ALL)","volume":"138","author":"Mart\u00ednez S\u00e1nchez","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol [Internet]"},{"issue":"36","key":"10.1016\/j.blre.2023.101042_bb0105","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol [Internet]"},{"issue":"16","key":"10.1016\/j.blre.2023.101042_bb0110","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol [Internet]"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101042_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-137350","article-title":"Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)","volume":"136","author":"Goekbuget","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0125","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2023.101042_bb0130","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood [Internet]"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101042_bb0135","article-title":"A phase 4 study to evaluate outpatient blinatumomab in patients with minimal\/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL)","volume":"39","author":"Khan","year":"2021"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00277-019-03854-0","article-title":"Safety and efficacy of blinatumomab: a real world data","volume":"99","author":"Apel","year":"2020","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101042_bb0145","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","article-title":"Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101042_bb0150","article-title":"A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed\/refractory (R\/R) B-cell precursor acute lymphoblastic leukemia (ALL)","volume":"40","author":"Papayannidis","year":"2022"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101042_bb0155","article-title":"Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study","volume":"39","author":"Short","year":"2021"},{"key":"10.1016\/j.blre.2023.101042_bb0160","author":"Litzow","year":"2022"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","article-title":"Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia","volume":"3","author":"Wynne","year":"2019","journal-title":"Blood Adv"},{"issue":"4856","key":"10.1016\/j.blre.2023.101042_bb0170","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.blre.2023.101042_bb0175","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/curroncol28010027","article-title":"Reevaluating patient eligibility for inotuzumab ozogamicin based on CD22 expression: is dim expression sufficient?","volume":"28","author":"Fingrut","year":"2021","journal-title":"Current Oncology"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0185","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/hon.3029","article-title":"Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment","volume":"40","author":"Sartor","year":"2022","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101042_bb0190","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia in the INO-VATE Trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22","volume":"27","author":"Kantarjian","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0195","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2011.206","article-title":"The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells","volume":"26","author":"de Vries","year":"2012","journal-title":"Leukemia [Internet]"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0210","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci [Internet]"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0215","article-title":"Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"46","author":"Garrett","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn [Internet]"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0220","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1208\/s12248-016-9929-7","article-title":"Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK\/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin","volume":"18","author":"Betts","year":"2016","journal-title":"AAPS J [Internet]"},{"issue":"17","key":"10.1016\/j.blre.2023.101042_bb0225","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.4155\/bio-2018-0259","article-title":"Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials","volume":"11","author":"Carrasco-Triguero","year":"2019","journal-title":"Bioanalysis [Internet]"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0230","first-page":"e77","article-title":"Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin","volume":"191","author":"Cassaday","year":"2020","journal-title":"Br J Haematol [Internet]"},{"issue":"15","key":"10.1016\/j.blre.2023.101042_bb0235","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer [Internet]"},{"issue":"21","key":"10.1016\/j.blre.2023.101042_bb0240","article-title":"A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage","volume":"124","author":"Advani","year":"2014","journal-title":"Blood [Internet]"},{"issue":"14","key":"10.1016\/j.blre.2023.101042_bb0245","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer [Internet]"},{"issue":"10","key":"10.1016\/j.blre.2023.101042_bb0250","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer [Internet]"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0255","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.clml.2020.03.004","article-title":"Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin","volume":"20","author":"Badar","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101042_bb0260","first-page":"100294","article-title":"Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"17","author":"Ueda","year":"2022","journal-title":"Leuk Res Rep"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0265","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.blre.2023.101042_bb0270","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood.2020008544","article-title":"Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL","volume":"137","author":"Kirchhoff","year":"2021","journal-title":"Blood [Internet]"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0275","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/hon.2886","article-title":"Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant","volume":"39","author":"Papayannidis","year":"2021","journal-title":"Hematol Oncol [Internet]"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101042_bb0280","article-title":"Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R\/R PH+ ALL or CML in lymphoid blast phase (CML LBP)","volume":"38","author":"Jain","year":"2020"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0285","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0290","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/j.clml.2020.04.008","article-title":"Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy","volume":"20","author":"Alduailej","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101042_bb0295","series-title":"Rituximab: Modes of action, remaining dispute and future perspective","first-page":"2481","volume":"10","author":"Abulayha","year":"2014"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0300","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101042_bb0305","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM."},{"issue":"11","key":"10.1016\/j.blre.2023.101042_bb0310","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0315","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101042_bb0320","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0325","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia [Internet]"},{"issue":"6","key":"10.1016\/j.blre.2023.101042_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.blre.2023.101042_bb0335","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0340","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun [Internet]"},{"issue":"24","key":"10.1016\/j.blre.2023.101042_bb0345","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0350","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0355","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0360","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cyto.b.21891","article-title":"Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challenges","volume":"100","author":"Sarikonda","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0365","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cll.2021.03.012","article-title":"Hematopathologic Correlates of CAR T-Cell Therapy","volume":"41","author":"Dolan","year":"2021","journal-title":"Clin Lab Med [Internet]"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151178","article-title":"Tisagenlecleucel therapy: nursing considerations for the outpatient setting","volume":"37","author":"Cunningham","year":"2021","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0380","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica [Internet]"},{"issue":"13_Supplement","key":"10.1016\/j.blre.2023.101042_bb0385","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-1631","article-title":"Abstract 1631: T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential","volume":"78","author":"Das","year":"2018","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0390","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0395","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101042_bb0400","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2023.101042_bb0405","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101042_bb0410","author":"FDA"},{"issue":"16","key":"10.1016\/j.blre.2023.101042_bb0415","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0420","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101042_bb0425","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with Relapsed\/Refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101042_bb0430","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia [Internet]"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0435","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.clml.2020.12.010","article-title":"Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes","volume":"21","author":"Aamir","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101042_bb0445","article-title":"Tisagenlecleucel (Tisa) for relapsed\/refractory (r\/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO)","volume":"38","author":"Krueger","year":"2020"},{"issue":"22","key":"10.1016\/j.blre.2023.101042_bb0450","article-title":"Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1\/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed\/Refractory B-Precursor Acute Lymphoblastic Leukemia (R\/R ALL)","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0455","author":"Shah"},{"issue":"10299","key":"10.1016\/j.blre.2023.101042_bb0460","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2021014892","article-title":"Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia","volume":"140","author":"Frey","year":"2022","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101042_bb0470","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101042_bb0475","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-137233","article-title":"ZUMA-4: A Phase 1\/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed\/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","volume":"136","author":"Wayne","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101042_bb0480","series-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment.","volume":"22","author":"Cosenza","year":"2021"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0485","first-page":"1","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Experiment Clin Cancer Res [Internet]"},{"issue":"6","key":"10.1016\/j.blre.2023.101042_bb0490","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0495","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0500","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"issue":"41","key":"10.1016\/j.blre.2023.101042_bb0505","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.intimp.2016.10.017","article-title":"Blinatumomab provoked fatal heart failure","volume":"1","author":"Darvishi","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"26","key":"10.1016\/j.blre.2023.101042_bb0515","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0520","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"24","key":"10.1016\/j.blre.2023.101042_bb0525","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood [Internet]"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0530","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med [Internet]"},{"issue":"499","key":"10.1016\/j.blre.2023.101042_bb0535","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med [Internet]"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0545","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","article-title":"Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events","volume":"80","author":"Klinger","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0550","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0555","article-title":"Assessment of coma and impaired consciousness a practical scale","volume":"28","author":"Teasdale Bryan Jennett","year":"1971","journal-title":"J Cancer in Five Continents"},{"key":"10.1016\/j.blre.2023.101042_bb0560","series-title":"\u201cMini-mental state\u201d a practical method for grading the cognitive state of patients for the clinician*","volume":"12","author":"Folstein","year":"1975"},{"key":"10.1016\/j.blre.2023.101042_bb0565","series-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","first-page":"552","volume":"56","author":"Sheth","year":"2021"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0570","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann Hematol [Internet]"},{"issue":"7","key":"10.1016\/j.blre.2023.101042_bb0575","article-title":"Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia","volume":"68","author":"Filippidou","year":"2021","journal-title":"Pediatr Blood Cancer [Internet]"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0585","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0590","doi-asserted-by":"crossref","unstructured":"Shah N.N., Johnson B.D., Fenske T.S., Raj R.V., Hari P. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 2020 May 26;4(10):2119-2122.","DOI":"10.1182\/bloodadvances.2020001626"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0595","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1177\/1078155218817817","article-title":"Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease","volume":"25","author":"Chen","year":"2019","journal-title":"J Oncol Pharm Pract [Internet]"},{"issue":"1\u20132","key":"10.1016\/j.blre.2023.101042_bb0600","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jneuroim.2010.03.022","article-title":"The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates","volume":"223","author":"Fox","year":"2010","journal-title":"J Neuroimmunol [Internet]"},{"issue":"22","key":"10.1016\/j.blre.2023.101042_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225607","article-title":"Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"13","author":"Kantarjian","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0610","doi-asserted-by":"crossref","first-page":"E167","DOI":"10.1097\/MPH.0000000000001532","article-title":"Bone marrow necrosis in a patient following blinatumomab therapy","volume":"42","author":"Yarali","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0615","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in Neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.blre.2023.101042_bb0620","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer."},{"issue":"15","key":"10.1016\/j.blre.2023.101042_bb0625","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv [Internet]"},{"issue":"23","key":"10.1016\/j.blre.2023.101042_bb0630","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0635","series-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0640","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0645","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001225","article-title":"Tisagenlecleucel infusion in patients with relapsed\/refractory ALL and concurrent serious infection","volume":"9","author":"Hall","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0650","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ccr3.2918","article-title":"Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy","volume":"8","author":"Tambaro","year":"2020","journal-title":"Clin Case Rep"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.blre.2023.101042_bb0660","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T Cell Toxicity: Current Management and Future Directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0665","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.blre.2023.101042_bb0670","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2169\/internalmedicine.4440-20","article-title":"Clinical significance of inotuzumab ozogamicin in non-transplant patients with relapsed acute lymphoblastic leukemia: A report of four cases","volume":"59","author":"Okura","year":"2020","journal-title":"Intern Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101042_bb0675","first-page":"6023","article-title":"Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based","volume":"140","author":"de Lima","year":"2022","journal-title":"Observat Study Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0680","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0685","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101042_bb0690","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e19024","article-title":"Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT)","volume":"39","author":"Cahill","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0700","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2023.101042_bb0705","unstructured":"Cber Fda Package Insert - TECARTUS [Internet] Available from:. www.fda.gov\/medwatch; 2023, January 20th."},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0710","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1159\/000509934","article-title":"Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress","volume":"45","author":"Matuszkiewicz-Rowinska","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.blre.2023.101042_bb0715","unstructured":"Fda Highlights of prescribing information [Internet] Available from:. www.fda.gov\/medwatch; 2023, January 20th."},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0720","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist [Internet]"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0725","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/bcp.13832","article-title":"Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling","volume":"85","author":"Hibma","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"10.1016\/j.blre.2023.101042_bb0730","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0735","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40273-019-00812-6","article-title":"Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States","volume":"37","author":"Delea","year":"2019","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0740","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1007\/s12325-022-02201-6","article-title":"Cost-Effectiveness of KTE-X19 for Adults with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States","volume":"39","author":"Shah","year":"2022","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0745","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1007\/s12325-022-02201-6","article-title":"Cost-Effectiveness of KTE-X19 for Adults with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States","volume":"39","author":"Shah","year":"2022","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0750","doi-asserted-by":"crossref","first-page":"255.e1","DOI":"10.1016\/j.jtct.2020.12.020","article-title":"Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies","volume":"27","author":"Aldoss","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0755","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101042_bb0760","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1705370","article-title":"Autologous stem cell transplant in ALL: Who should we be transplanting in first remission?","volume":"37","author":"Mato","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101042_bb0765","series-title":"Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state","first-page":"195","volume":"11","author":"Saadeh","year":"2018"},{"issue":"4","key":"10.1016\/j.blre.2023.101042_bb0770","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41409-020-01101-z","article-title":"Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia","volume":"56","author":"Greil","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101042_bb0775","series-title":"Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission","volume":"22","author":"Arslan","year":"2021"},{"issue":"1\u20132","key":"10.1016\/j.blre.2023.101042_bb0780","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s44228-022-00006-6","article-title":"Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?","volume":"4","author":"Komitopoulou","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"14","key":"10.1016\/j.blre.2023.101042_bb0785","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome\u2013negative adult lymphoblastic leukemia","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0790","series-title":"Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?","first-page":"143","volume":"12","author":"Dhawan","year":"2017"},{"issue":"20","key":"10.1016\/j.blre.2023.101042_bb0795","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/bloodadvances.2020002945","article-title":"Allogeneic transplantation for Ph1 acute lymphoblastic leukemia with posttransplantation cyclophosphamide","volume":"4","author":"Webster","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101042_bb0800","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nature Rev Clin Oncol Nat Res"},{"key":"10.1016\/j.blre.2023.101042_bb0805","first-page":"7","article-title":"Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia","volume":"12","author":"Hein","year":"2022","journal-title":"Blood Lymphat Cancer [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0810","article-title":"Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"88","author":"Jabbour","year":"2020","journal-title":"Leuk Res [Internet]"},{"key":"10.1016\/j.blre.2023.101042_bb0815","series-title":"Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia","author":"Qiufei","year":"2019"},{"issue":"5","key":"10.1016\/j.blre.2023.101042_bb0820","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2021005978","article-title":"Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab","volume":"6","author":"Wudhikarn","year":"2022","journal-title":"Blood Adv [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0825","first-page":"1","article-title":"Inotuzumab ozogamicin is effective in relapsed\/refractory extramedullary B acute lymphoblastic leukemia 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology","volume":"18","author":"Bertamini","year":"2018","journal-title":"BMC Cancer [Internet]"},{"issue":"22","key":"10.1016\/j.blre.2023.101042_bb0830","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0835","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/10428194.2019.1641802","article-title":"Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: How to select newly approved agents?","volume":"61","author":"Dhakal","year":"2020","journal-title":"Leuk Lymphoma [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101042_bb0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2021000225","article-title":"CAR T vs transplant vs novel therapies","volume":"2021","author":"Frey","year":"2021","journal-title":"Hematology [Internet]"},{"issue":"23","key":"10.1016\/j.blre.2023.101042_bb0845","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1182\/bloodadvances.2020004045","article-title":"Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"5","author":"Verneris","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101042_bb0850","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/ajco.13609","article-title":"Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"18","author":"Kobayashi","year":"2022","journal-title":"Asia Pac J Clin Oncol [Internet]"},{"issue":"9","key":"10.1016\/j.blre.2023.101042_bb0855","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 -4 and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol [Internet]"},{"issue":"8","key":"10.1016\/j.blre.2023.101042_bb0860","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"New England Journal of Medicine [Internet]"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101042_bb0865","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016"},{"issue":"22","key":"10.1016\/j.blre.2023.101042_bb0870","article-title":"Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed\/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis","volume":"128","author":"Maude","year":"2016","journal-title":"Blood [Internet]"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:49Z","timestamp":1759437049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":170,"alternative-id":["S0268960X23000036"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101042","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101042"}}